Cited by 169Gut microbiota and healthLiver Disease Diagnosis and TreatmentAlcohol Consumption and Health Effects

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Intestinal microbiota and nonalcoholic steatohepatitis

Open access

Brandl, Katharina, Schnabl, Bernd·2017·Current Opinion in Gastroenterology

DOI 10.1097/mog.0000000000000349PMC PMC5662009

Open this paper in CoChat — free account

Abstract

PURPOSE OF REVIEW: Nonalcoholic fatty liver disease (NAFLD) is a liver disease with high prevalence in western countries. Progression from NAFLD to nonalcoholic steatohepatitis (NASH) occurs in 10-20%. NASH pathogenesis is multifactorial including genetic and environmental factors. The gut microbiota is involved in disease progression and its role is complex. RECENT FINDINGS: NASH is associated with changes in the intestinal microbiota, although findings in recent studies are inconsistent. Dysbiosis can trigger intestinal inflammation and impair the gut barrier. Microbial products can now reach the liver, induce hepatic inflammation and contribute to NAFLD and NASH progression. As the gut microbiota is also involved in the regulation of metabolic pathways, metabolomic approaches identified unique metabolomic profiles in patients with NASH. Altered metabolite patterns can serve as biomarkers, whereas specific metabolites (such as ethanol) have been linked with disease progression. Modifying metabolic profiles might serve as new therapeutic microbiome-based approaches. SUMMARY: In this review, we will highlight findings from the recent literature important to the gut-liver axis. We will predominantly focus on human studies with NASH.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1097/mog.0000000000000349

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

An obesity-associated gut microbiome with increased capacity for energy harvest
Turnbaugh, P. J., Ley, R. E., Mahowald, M. A., Magrini, V., Mardis, E. R., & Gordon, J. I. (2006) · Nature · doi:10.1038/nature05414 · Cited by 12,444
Diet rapidly and reproducibly alters the human gut microbiome
David, L. A., Maurice, C. F., Carmody, R. N., Gootenberg, D. B., Button, J. E., Wolfe, B. E., Ling, A. V., Devlin, A. S., Varma, Y., Fischbach, M. A., et al. (2014) · Nature · doi:10.1038/nature12820 · Cited by 10,100
Human gut microbiome viewed across age and geography
Yatsunenko, T., Rey, F. E., Manary, M. J., Trehan, I., Dominguez-Bello, M. G., Contreras, M., Magris, M., Hidalgo, G., Baldassano, R. N., Anokhin, A. P., et al. (2012) · Nature · doi:10.1038/nature11053 · Cited by 7,815
Changes of Intestinal Functions in Liver Cirrhosis
Fukui, H., & Wiest, R. (2016) · Inflammatory Intestinal Diseases · doi:10.1159/000444436 · Cited by 6,820
The gut microbiota as an environmental factor that regulates fat storage
Bäckhed, F., Ding, H., Wang, T., Hooper, L. V., Koh, G. Y., Nagy, A., Semenkovich, C. F., & Gordon, J. I. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407076101 · Cited by 6,245
Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity
Henao-Mejia, J., Elinav, E., Jin, C., Hao, L., Mehal, W. Z., Strowig, T., Thaiss, C. A., Kau, A. L., Eisenbarth, S. C., Jurczak, M. J., et al. (2012) · Nature · doi:10.1038/nature10809 · Cited by 2,435
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): A multicentre, randomised, placebo-controlled trial
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
Are We Really Vastly Outnumbered? Revisiting the Ratio of Bacterial to Host Cells in Humans
Sender, R., Fuchs, S., & Milo, R. (2016) · Cell · doi:10.1016/j.cell.2016.01.013 · Cited by 2,050
Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: A connection between endogenous alcohol and NASH
Zhu, L., Baker, S. S., Gill, C., Liu, W., Alkhouri, R., Baker, R. D., & Gill, S. R. (2013) · Hepatology · doi:10.1002/hep.26093 · Cited by 1,708
The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota
Boursier, J., Mueller, O., Barret, M., Machado, M., Fizanne, L., Araujo‐Perez, F., Guy, C. D., Seed, P. C., Rawls, J. F., David, L. A., et al. (2016) · Hepatology · doi:10.1002/hep.28356 · Cited by 1,483

Show all 42 references

Sorted by citations

Items 101–168 of 168

COVID-19 Pandemic: Insights into Interactions between SARS-CoV-2 Infection and MAFLD
Chen, H., & Chen, Q. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.72461 · Cited by 16
Cholecystectomy as a risk factor for metabolic dysfunction-associated fatty liver disease: unveiling the metabolic and chronobiologic clues behind the bile acid enterohepatic circulation
Li, Q., Dai, W., Kong, J., Tian, Y., & Chen, Y. (2021) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-020-00782-w · Cited by 15
Research progress regarding the effect and mechanism of dietary phenolic acids for improving nonalcoholic fatty liver disease via gut microbiota
Ji, L., Deng, H., Xue, H., Wang, J., Hong, K., Gao, Y., Kang, X., Fan, G., Huang, W., Zhan, J., et al. (2023) · Comprehensive Reviews in Food Science and Food Safety · doi:10.1111/1541-4337.13106 · Cited by 16
Application of metabolomics in the diagnosis of non-alcoholic fatty liver disease and the treatment of traditional Chinese medicine
Shao, M., Lu, Y., Xiang, H., Wang, J., Ji, G., & Wu, T. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.971561 · Cited by 14
Human liver microbiota modeling strategy at the early onset of fibrosis
Champion, C., Neagoe, R. M., Effernberger, M., Sala, D. T., Servant, F., Christensen, J. E., Arnoriaga‐Rodríguez, M., Amar, J., Lelouvier, B., Loubières, P., et al. (2023) · BMC Microbiology · doi:10.1186/s12866-023-02774-4 · Cited by 14
Non-alcoholic fatty liver disease: A poorly known pandemic
Augustín, S., Graupera, I., & Caballería, J. (2017) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2017.11.009 · Cited by 14
Higher bacterial DNAemia can affect the impact of a polyphenol-rich dietary pattern on biomarkers of intestinal permeability and cardiovascular risk in older subjects
Gargari, G., Taverniti, V., Bo’, C. D., Bernardi, S., Hidalgo‐Liberona, N., Meroño, T., Andrés‐Lacueva, C., Kroon, P. A., Cherubini, A., Riso, P., et al. (2021) · European Journal of Nutrition · doi:10.1007/s00394-021-02680-3 · Cited by 14
Relations of gut liver axis components and gut microbiota in obese children with fatty liver: A pilot study
Pierri, L., Saggese, P., Nuzio, S. G., Troisi, J., Stasi, M. D., Poeta, M., Savastano, R., Marchese, G., Tarallo, R., Massa, G., et al. (2018) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2018.03.015 · Cited by 14
Gut Microbiota as an Emerging Therapeutic Avenue for the Treatment of Nonalcoholic Fatty Liver Disease
Ralli, T., Neupane, Y. R., Saifi, Z., & Kohli, K. (2021) · Current Pharmaceutical Design · doi:10.2174/1389201022666210625141526 · Cited by 14
Proglumide Reverses Nonalcoholic Steatohepatitis by Interaction with the Farnesoid X Receptor and Altering the Microbiome
Gay, M. D., Cao, H., Shivapurkar, N., Dakshanamurthy, S., Kallakury, B., Tucker, R. D., Kwagyan, J., & Smith, J. P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031899 · Cited by 14
Healthy diet intervention reverses the progression of NASH through gut microbiota modulation
Panyod, S., Wu, W., Hu, M.-Y., Huang, H., Chen, R.-A., Chen, Y., Shen, T. D., Ho, C., Liu, C., Chuang, H.-L., et al. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.01868-23 · Cited by 14
Metabolomic Study of High-Fat Diet-Induced Obese (DIO) and DIO Plus CCl4-Induced NASH Mice and the Effect of Obeticholic Acid
Zhu, N.-L., Huang, S., Zhang, Q., Zhao, Z., Qu, H. Y., Ning, M., Leng, Y., & Liu, J. (2021) · Metabolites · doi:10.3390/metabo11060374 · Cited by 13
Mouse models of nonalcoholic steatohepatitis and their application to new drug development
Phung, H. H., & Lee, C. H. (2022) · Archives of Pharmacal Research · doi:10.1007/s12272-022-01410-5 · Cited by 13
Gut Microbial Perturbation and Host Response Induce Redox Pathway Upregulation along the Gut–Liver Axis during Giardiasis in C57BL/6J Mouse Model
Karpe, A. V., Hutton, M. L., Mileto, S. J., James, M. L., Evans, C., Ghodke, A. B., Shah, R., Metcalfe, S. S., Liu, J., Walsh, T., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021636 · Cited by 11
Nonalcoholic Fatty Liver Disease and the Intestinal Microbiome: An Inseparable Link
Effenberger, M., Grander, C., Grabherr, F., & Tilg, H. (2023) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2023.00069 · Cited by 14
Microbiota–Liver Diseases Interactions
Capparelli, R., Cuomo, P., Gentile, A., & Iannelli, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043883 · Cited by 12
Leber-Darm-Achse: Wie Darmbakterien die Leber beeinflussen
Konturek, P. C., Harsch, I. A., Konturek, K., Schink, M., & Zopf, Y. (2018) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-018-1051-6 · Cited by 12
Individuals with Metabolic Syndrome Show Altered Fecal Lipidomic Profiles with No Signs of Intestinal Inflammation or Increased Intestinal Permeability
Coleman, M. J., Espino, L. M., Lebensohn, H., Zimkute, M. V., Yaghooti, N., Ling, C. L., Gross, J., Listwan, N., Cano, S., Garcia, V., et al. (2022) · Metabolites · doi:10.3390/metabo12050431 · Cited by 12
Steatotic Liver Disease and Sepsis Outcomes—A Prospective Cohort Study (SepsisFAT)
Krznarić, J., Papić, N., Vrsaljko, N., Gjurašin, B., Kutleša, M., & Vince, A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13030798 · Cited by 11
Inflammasome-Mediated Cytokines: A Key Connection between Obesity-Associated NASH and Liver Cancer Progression
da Cruz, N. S., Pasquarelli-do-Nascimento, G., Oliveira, A. C. P. E., & Magalhães, K. G. (2022) · Biomedicines · doi:10.3390/biomedicines10102344 · Cited by 10
Mechanism of Metabolic Response to Hepatectomy by Integrated Analysis of Gut Microbiota, Metabolomics, and Proteomics
He, R., Gao, S., Yao, H., Zhao, Z., Tong, J., & Zhang, H. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.02067-22 · Cited by 11
Single-cell transcriptomics unveiled that early life BDE-99 exposure reprogrammed the gut-liver axis to promote a proinflammatory metabolic signature in male mice at late adulthood
Lim, J. J., Goedken, M. J., Jin, Y., Gu, H., & Cui, J. Y. (2024) · Toxicological Sciences · doi:10.1093/toxsci/kfae047 · Cited by 8
Intestinal microbiota in the treatment of metabolically associated fatty liver disease
Wang, J.-S., & Liu, J. (2022) · World Journal of Clinical Cases · doi:10.12998/wjcc.v10.i31.11240 · Cited by 8
Vegetal oil-based ketogenic diet improves inflammation and fibrosis in experimental metabolic dysfunction-associated steatohepatitis
Provera, A., Ramavath, N. N., Gadipudi, L. L., Vecchio, C., Caputo, M., Antonioli, A., Tini, S., Sheferaw, A. N., Reano, S., Filigheddu, N., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1518687 · Cited by 7
Gut microbial signatures associated with the Indian lean MASLD phenotype
Dey, P. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1673517 · Cited by 8
Promising diagnostic biomarkers of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: From clinical proteomics to microbiome
Castillo-Castro, C., Martagón, A. J., Ortíz-López, R., Garrido-Trevino, L., Villegas-Albo, M., & Bosques‐Padilla, F. (2021) · World Journal of Hepatology · doi:10.4254/wjh.v13.i11.1494 · Cited by 8
In Vitro, In Vivo, and In Silico Investigation of Synbiotic‐Mediated Activation of PPAR‐ α Curtails Nonalcoholic Steatohepatitis (NASH) in Wistar Rats by Inhibiting PNPLA3/SREBP1‐c Lead Inflammatory Injury of Hepatic Cells
Sharma, D., Patel, D. N., & Mandal, P. (2025) · Mediators of Inflammation · doi:10.1155/mi/9948679 · Cited by 6
The pathogenesis of liver fibrosis in Wilson’s disease: hepatocyte injury and regulation mediated by copper metabolism dysregulation
Ma, Y., Pu, Y., Chen, H., Zhou, L., Yang, B., Huang, X., & Zhang, J. (2025) · BioMetals · doi:10.1007/s10534-025-00748-9 · Cited by 8
Succinylsulfathiazole modulates the mTOR signaling pathway in the liver of c57BL/6 mice via a folate independent mechanism
Beydoun, S., Fardous, A. M., Saruna, M. M., Beydoun, A. G., Sorge, J. A., Ma, H., Aoun, G., Unnikrishnan, A., Cabelof, D. C., & Heydari, A. R. (2021) · Experimental Gerontology · doi:10.1016/j.exger.2021.111387 · Cited by 6
Obesity and NAFLD
Cordero, P., Li, J., & Oben, J. A. (2017) · Endocrinology · doi:10.1007/978-3-319-47685-8_20-1 · Cited by 6
Die Rolle des Darmmikrobioms bei chronischen Krankheiten: Eine narrative Übersichtsarbeit
Vijay, A., & Valdes, A. M. (2022) · Kompass Autoimmun · doi:10.1159/000524069 · Cited by 5
The Challenging Ethical Landscape of Non-alcoholic Fatty Liver Disease
Berry, P., & Kotha, S. (2022) · EMJ Hepatology · doi:10.33590/emjhepatol/21-00217 · Cited by 5
Development of non-alcoholic steatohepatitis is associated with gut microbiota but not with oxysterol enzymes CH25H, EBI2, or CYP7B1 in mice
Wyss, J., Raselli, T., Wyss, A., Telzerow, A., Rogler, G., Krupka, N., Yılmaz, B., Schmidt, T., & Misselwitz, B. (2024) · BMC Microbiology · doi:10.1186/s12866-024-03195-7 · Cited by 4
Observational study protocol: the faecal microbiome in the acute stage of new-onset paediatric type 1 diabetes in an Irish cohort
Kennedy, E. C., Ross, F. C., O'Shea, C., Lavelle, A., Ross, R. P., Dempsey, E. M., Stanton, C., & Hawkes, C. P. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-089206 · Cited by 4
Non-alcoholic fatty liver disease - opportunities for personalized treatment and drug development
Kemas, A. M., Youhanna, S. C., & Lauschke, V. M. (2022) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2022.2053285 · Cited by 4
GLP-1 receptor agonists in metabolic dysfunction–associated steatotic liver disease: mechanistic networks and translational implications: a review
Wang, X., Lu, G., Zhou, Y., & Zhao, G. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-02891-7 · Cited by 2
Die Darm-Leber-Achse bei nichtalkoholischer Fettlebererkrankung: molekulare Mechanismen und neue Targets
Schneider, K. M., & Trautwein, C. (2020) · Wiener klinisches Magazin · doi:10.1007/s00740-020-00353-1 · Cited by 2
Non-alcoholic fatty liver disease: Is surgery the best current option and can novel endoscopy play a role in the future?
Mandour, M. O., El-Hassan, M., Elkomi, R., & Oben, J. A. (2022) · World Journal of Hepatology · doi:10.4254/wjh.v14.i9.1704 · Cited by 2
Global Trends of Treatment for NAFLD from 2012 to 2021: A Bibliometric and Mapping Analysis
Song, Y., Chen, B., Jiang, L., Zhao, F., & Feng, X. (2023) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/0118715303230418230925060312 · Cited by 2
Identifying Causal Relations between Gut Microbiome, Metabolic Dysfunction-Associated Fatty Liver Disease and the Novel Mediators of Blood MetabolitesPreprint
Yi, X., Zhu, H., He, M., Zhong, L., Gao, S., & Li, M. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.08.05.606637 · Cited by 2
Therapeutic Role of Bone Marrow Mesenchymal Stem Cells (BMSCs) in Nonalcoholic Steatohepatitis (NASH) Cirrhosis
Jiang, H.-T., Ye, H.-M., Yu, H.-Y., Zhu, Y., Hu, M., He, M., Li, W., Yu, Z., Yang, Q., He, L., et al. (2024) · Current Stem Cell Research & Therapy · doi:10.2174/011574888x328447241023063825 · Cited by 1
Obesity and NAFLD
Cordero, P., Li, J., & Oben, J. A. (2019) · Endocrinology · doi:10.1007/978-3-319-46933-1_20 · Cited by 1
Understudied targets of the ischemia-reperfusion injury pathogenesis in liver transplantation
Svishcheva, P. O., Kanibolotskiy, A. A., Yaremin, B. I., Anosova, Е. Y., Karina, Y. S., Kaziakhmedova, Z. G., & Новрузбеков, М. С. (2024) · Transplantologiya The Russian Journal of Transplantation · doi:10.23873/2074-0506-2024-16-2-244-259 · Cited by 1
NAFLD in HIV mono-infection is a consequence of insulin resistance but not bacterial translocation
Maurice, J. B., Kelleher, P., Nelson, M., Thursz, M. R., & Lemoine, M. (2018) · Journal of Hepatology · doi:10.1016/s0168-8278(18)30940-1
The Use of Metabolomics to Explore the Gut-Liver Axis
Dragsted, L. O., & Trôst, K. (2018) · Springer eBooks · doi:10.1007/978-3-319-98890-0_10
Die Darm-Leber-Achse bei nichtalkoholischer Fettlebererkrankung: molekulare Mechanismen und neue Targets
Schneider, K. M., & Trautwein, C. (2020) · Die Gastroenterologie · doi:10.1007/s11377-019-00402-0
Gut Microbiota as Signatures in Non-communicable Diseases and Mucosal Immunity
Behera, S. K., Praharaj, A. B., Chalikonda, G., Srivani, G., & Mahapatra, N. (2020) · Diagnostics and therapeutic advances in GI malignancies · doi:10.1007/978-981-15-2017-4_11
Gut Microbiota and Host Cyp450s Co-contribute to Pharmacokinetic Variability in Mice With Non-Alcoholic Steatohepatitis: Vary From Drug to DrugPreprint
Guo, J., Xu, Y., Chen, L., Zhang, S.-X., Rao, T., Peng, J., Guo, Y., Tan, Z., Ouyang, D., Chen, X.-P., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-729728/v1
Bakterien im Mund–Freund oder Feind?
Schlafer, S. (2019) · Oralprophylaxe & Kinderzahnheilkunde · doi:10.3238/opkzh.2019.0169-0174
Development of non-alcoholic steatohepatitis is associated with gut microbiota but not oxysterol synthesisPreprint
Wyss, J., Raselli, T., Wyss, A., Telzerow, A., Rogler, G., Krupka, N., Yılmaz, B., Schmidt, T., & Misselwitz, B. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.12.02.518833
Oral supplementation of gut microbial metabolite indole-3-acetate alleviates diet-induced steatosis and inflammation in micePreprint
Ding, Y., Yanagi, K., Yang, F., Callaway, E. S., Cheng, C., Hensel, M. E., Menon, R., Alaniz, R. C., Lee, K., & Jayaraman, A. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.03.21.533660
Microbially-derived indole-3-acetate alleviates diet induced steatosis and inflammation in micePreprint
Ding, Y., Yanagi, K., Yang, F., Callaway, E. S., Cheng, C., Hensel, M. E., Menon, R., Alaniz, R. C., Lee, K., & Jayaraman, A. (2023) · eLife · doi:10.7554/elife.87458.1
Reviewer #1 (Public Review): Microbially-derived indole-3-acetate alleviates diet induced steatosis and inflammation in mice
(2023) · eLife · doi:10.7554/elife.87458.1.sa2
Oral supplementation of gut microbial metabolite indole-3-acetate alleviates diet-induced steatosis and inflammation in micePreprint
Ding, Y., Yanagi, K., Yang, F., Callaway, E. S., Cheng, C., Hensel, M. E., Menon, R., Alaniz, R. C., Lee, K., & Jayaraman, A. (2023) · eLife · doi:10.7554/elife.87458.2
Microbiote buccal et foie
Lê, S., Minty, M., Boyer, É., Blasco‐Baqué, V., Bonnaure‐Mallet, M., & Meuric, V. (2024) · médecine/sciences · doi:10.1051/medsci/2023194
Microbiome: Human Nutrition and Psychology
Tewari, S., Sarkar, L., Pramanik, P., Mukherjee, P., Pattanayak, A., & Mahreen, K. F. (2023) · International Journal of Indian Psychology · doi:10.25215/1103.110
The Role of the Intestinal Microbiota in NAFLD Onset and Progression
Pinheiro, I. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1007741
NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD): DISEASE MECHANISMS AND CONTEMPORARY THERAPEUTIC APPROACHES - A LITERATURE REVIEW
Strużek, K., Kwiatkowska, A., Mączka, E., Tracz, W., Świercz, P., Teper, K., Khiralla-Gawlik, S., Strzelecka, A. A., & Basak, A. E. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(47).2025.3662
Integrated therapies for targeting the microenvironment of hepatocellular carcinoma
Karunakaran, S., Ghanta, M. K., Cheetiyar, A. L., Bhaskar, L. V., & Nagaraju, G. P. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104556 · Cited by 1
Additional file 1 of Human liver microbiota modeling strategy at the early onset of fibrosis
Champion, C., Neagoe, R. M., Effernberger, M., Sala, D. T., Servant, F., Christensen, J. E., Arnoriaga‐Rodríguez, M., Amar, J., Lelouvier, B., Loubières, P., et al. (2023) · Figshare · doi:10.6084/m9.figshare.26564922
Additional file 1 of Exploring the interplay of gut microbiota, inflammation, and LDL-cholesterol: a multiomics Mendelian randomization analysis of their causal relationship in acute pancreatitis and non-alcoholic fatty liver disease
Yan, C., Bao, J., & Jin, J. (2024) · Figshare · doi:10.6084/m9.figshare.25248818
Additional file 1 of Compositional alterations of gut microbiota in nonalcoholic fatty liver disease patients: a systematic review and Meta-analysis
Li, F., Ye, J., Shao, C., & Zhong, B. (2021) · Figshare · doi:10.6084/m9.figshare.14129363
Yanxiao Di’naer decoction attenuates metabolic dysfunction-associated steatohepatitis through the regulation of gut microbiota and the metabolism of bile acid
Zheng, D.-X., Wang, Y., Hou, Q., Wen, L., Liu, J., Yin, Q., Yin, H.-L., Liu, Z., Hu, J.-P., & Yang, J.-H. (2026) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2026.121486
Effets préventifs des acides gras polyinsaturés en n-3 dans l’altération de la couche de mucus colique et du stress du réticulum endoplasmique induit par un régime obésogène.
Escoula, Q. (2020) · theses.fr (ABES) · doi:10.70675/81797e03zd364z4b09zaa86z993af56f01bf
Diversité des macrophages dans un modèle murin de stéatohépatite non alcoolique
Tran, S. (2019) · theses.fr (ABES) · doi:10.70675/22efc884z2788z43fazabc1zaeb115ea6833
Implications du microbiote intestinal et de la pectine dans la stéato-hépatite non-alcoolique
Houron, C. (2020) · theses.fr (ABES) · doi:10.70675/282e9d85z4f3dz4f5bz9045zd1ce6da72037
Research and development of innovative mathematical algorithms using cluster-based interactions of metagenomic data in biomedicine
Champion, C. (2021) · theses.fr (ABES) · doi:10.70675/79fd4203z5327z427bz9c20zcbb27d66da1b
Integrative omics perspectives on the gut-liver axis in chronic liver diseases: mechanisms and therapeutic potential
Zhong, J., Zheng, S., Zhao, X., Mei, C., Yang, Y., & Ye, Y. (2026) · Results in Chemistry · doi:10.1016/j.rechem.2026.103994

Authors: Brandl, K., & Schnabl, B.
Affiliations: University of California San Diego (US)
Corresponding author: Schnabl, Bernd
ORCID: Brandl, Katharina
Schnabl, Bernd
Venue: Current Opinion in Gastroenterology
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2017-05
Volume: 33
Issue: 3
Pages: 128-133
ISSN: 0267-1379 (ISSN-L)
DOI: 10.1097/mog.0000000000000349
PMC: PMC5662009
OpenAlex: W2593189168
Cited by: 169
References: 42
Citations by year: 2026: 3 · 2025: 9 · 2024: 17 · 2023: 25 · 2022: 24 · 2021: 32 · 2020: 20 · 2019: 15 · 2018: 18 · 2017: 6
FWCI: 1.51
Type: journal article
Language: en
Open access: green
europepmc.org
Locations: Current Opinion in Gastroenterology (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: U.S. Department of Veterans Affairs (I01BX002213)
National Institute on Alcohol Abuse and Alcoholism (R01AA020703, U01AA024726, U01AA021856)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
Keywords: nonalcoholic steatohepatitis, non-alcoholic fatty liver disease, gut microbiota, gut dysbiosis, gut-liver axis, intestinal inflammation, intestinal barrier, liver inflammation, metabolomics, metabolomic biomarkers, ethanol, microbiota-based therapy
MeSH terms: Gastrointestinal Microbiome, Humans, Disease Progression, Bacterial Translocation, Metabolomics, Dysbiosis, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Intestinal microbiota and nonalcoholic steatohepatitis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks